Finch Therapeutics Group, Inc.
Other OTCTotal Valuation
Finch Therapeutics Group, Inc. carries a market capitalization of 16.06M, placing it among publicly traded companies globally. Its enterprise value stands at 15.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 16.06M |
| Enterprise Value | 15.15M |
Share Statistics
Finch Therapeutics Group, Inc. currently has 1.61M shares outstanding.
| Shares Outstanding | 1.61M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.15 |
| P/FCF Ratio | -0.12 |
| P/OCF Ratio | -0.12 |
Financial Position
Finch Therapeutics Group, Inc. maintains a current ratio of 3.87, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.87 |
| Quick Ratio | 3.59 |
| Debt / Equity | 203.88 |
| Debt / EBITDA | -1.49 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -25.20 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Finch Therapeutics Group, Inc.'s stock has declined approximately -19.28975% over the past 52 weeks. The 50-day moving average sits at 12.77, while the 200-day moving average is 12.96.
| Beta (5Y) | N/A |
| 52-Week Price Change | -19.28975% |
| 50-Day Moving Average | 12.77 |
| 200-Day Moving Average | 12.96 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -19.51M, while operating income came in at -19.69M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -19.69M |
| Pretax Income | -14.17M |
| Net Income | -14.17M |
| EBITDA | -19.51M |
| EBIT | -19.69M |
| Earnings Per Share (EPS) | -8.82 |
Balance Sheet
Finch Therapeutics Group, Inc. holds 16.04M in cash and equivalents against 28.99M in total debt, resulting in a net debt position of -16.03M. Total book value stands at -359.10M, with working capital of 12.82M providing operational flexibility.
| Cash & Cash Equivalents | 16.04M |
| Total Debt | 28.99M |
| Net Debt | -16.03M |
| Equity (Book Value) | -359.10M |
| Book Value Per Share | -223.67 |
| Working Capital | 12.82M |
Cash Flow
Finch Therapeutics Group, Inc. produced -18.05M in operating cash flow over the past twelve months. After subtracting 14,000.00 in capital expenditures, free cash flow totaled -18.04M - equivalent to -11.24 per share.
| Operating Cash Flow | -18.05M |
| Capital Expenditures | 14,000.00 |
| Free Cash Flow | -18.04M |
| FCF Per Share | -11.24 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -821.49 |
Stock Splits
Finch Therapeutics Group, Inc.'s most recent stock split took place on June 12, 2023 with a 30:1 split ratio.
| Last Split Date | 6/12/2023 |
| Split Ratio | 30:1 |
Scores
Finch Therapeutics Group, Inc. posts an Altman Z-Score of -12.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.08 |